# Bupivacaine Liposome Suspension Administration to Decreasre Peri-procedural Pain in Interventional Radiology (IR) Procedures

> **NCT07535411** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Analgesia Assessment

## Interventions

- **DRUG:** Liposomal Bupivacaine (EXPAREL®)/Bupivacaine

## Key facts

- **NCT ID:** NCT07535411
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2026-06
- **Final completion:** 2026-07
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07535411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07535411, "Bupivacaine Liposome Suspension Administration to Decreasre Peri-procedural Pain in Interventional Radiology (IR) Procedures". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07535411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*